[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bluefin Biomedicine, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100615057",false,"NCT07287644","A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa","A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Moderate to Severe Hidradenitis Suppurativa","COMPASS 2-HS","Inclusion Criteria:\n\n* Are adults (18 to 75 years) with a diagnosis of hidradenitis suppurativa for at least one year.\n* Have moderate to severe disease not well controlled by systemic antibiotic treatment.\n* Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.\n\nExclusion Criteria:\n\n* Have certain infections or other immune conditions.\n* Recently used medications that could interfere with the study.\n* Are pregnant or breastfeeding.","ALL","18 Years","75 Years",{"count":20,"type":21},210,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.",[28],"Hidradenitis Suppurativa (HS)",[30,31],"Hidradenitis Suppurativa","acne inversa","RECRUITING","2026-05-28",{"date":35,"type":36},"2026-05-29","ACTUAL",{"date":38,"type":36},"2025-11-03",{"date":40,"type":21},"2027-08-01",{"name":42,"class":43},"Bluefin Biomedicine, Inc.","INDUSTRY",58,{"id":46,"slug":4,"hasResults":10,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":26,"conditions":55,"keywords":57,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100601053","NCT07105488","A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis","A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Atopic Dermatitis (COMPASS 2-AD)","COMPASS 2-AD","Inclusion Criteria:\n\n* Are adults (18-75) with a diagnosis of atopic dermatitis for at least one year.\n* Have moderate to severe disease not adequately controlled by topical treatments.\n* Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.\n\nExclusion Criteria:\n\n* Have certain infections or other immune conditions.\n* Recently used medications that could interfere with the study.\n* Are pregnant or breastfeeding.",{"count":53,"type":21},225,[24],[56],"Atopic Dermatitis (AD)",[58,59],"Atopic Dermatitis","Eczema",{"date":35,"type":36},{"date":62,"type":36},"2025-07-15",{"date":64,"type":21},"2027-03-31",{"name":42,"class":43},88,""]